Shares of Germany’s 4SC ($VSC) surged 35% after investigators reported promising mid-stage data for the cancer drug resminostat, an HDAC inhibitor, in difficult-to-treat patients with advanced liver cancer.
4SC will now head to ASCO with data from a sm…
Archive for the ‘4SC AG’ Category
4SC surges on positive midstage data for advanced liver cancer
January 19th, 2012 
John Carroll 
Posted in 4SC AG, Acetylon Pharmaceuticals, ASCO, Blog, Companies, Curis, Diagnostics, Funding, Medical Devices, Medical Supply, Nexavar, Pharmaceuticals, Startups, Universities, Videos 
Tags: biotech food social media 
Comments Off